Litigation Details for NOVARTIS PHARMACEUTICALS CORPORATION v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)

NOVARTIS PHARMACEUTICALS CORPORATION v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)

Docket		Date Filed	2014-12-02
Court	District Court, D. New Jersey	Date Terminated	2015-12-01
Cause	35:271 Patent Infringement	Assigned To	Susan Davis Wigenton
Jury Demand	None	Referred To	Leda Dunn Wettre
Patents	8,324,189
Link to Docket	External link to docket

Details for NOVARTIS PHARMACEUTICALS CORPORATION v. SAGENT PHARMACEUTICALS, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-12-02	1		prior to the expiration of U.S. Patent No. 8,324,189 (“the ’189 patent”). … ’189 patent. A copy of the ’189 patent is attached as Exhibit A. The claims of the ’189 patent are valid… 2. This is an action for patent infringement under the patent laws of the United States, Title…concentrate. B. The Patent-In-Suit 13. The ’189 patent, entitled “Use of zolendronate…covered by certain claims of the ’189 patent. Accordingly, the ’189 patent is listed in connection with Zometa	External link to document
2015-06-11	6		mL ANDA Product infringes U.S. Patent No. 8.324.189 (“the 189 patent”) and that. upon approval, the commercial…Corporation (“Novartis”) has asserted in this patent infringement suit that the filing of the Sagent…4 mg 5 mL ANDA Product will infringe the ‘189 patent (Civil Action No. 2:1 4-cv-07556-SDW-SCM (“this…enforceability, and infringement of the ‘1 89 patent with regard to, among other things, Sagent’s … WHEREAS. Sagent asserts that the ‘189 patent is invalid and not infringed by the Sagent 4	External link to document